Stroke worry and QoL issues sway US panel against Abiomed's artificial heart
This article was originally published in Clinica
Executive Summary
The introduction in the US of a total artificial heart (TAH) as a last-ditch treatment for the most sick cardiac patients needs to be put on hold until various safety questions are answered, a deeply divided FDA advisory committee on June 23.